MedWatch

Fate of Biogen’s stock rides on Alzheimer’s drug decision

For Biogen, the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called "the mother of all binary events" -- one that could send its shares veering sharply in either direction.

Photo: BRIAN SNYDER/REUTERS / X90051

For Biogen, the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called "the mother of all binary events" -- one that could send its shares veering sharply in either direction.

If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to USD 450, according to Wall Street analysts. Or it could tumble to USD 200 if the treatment is shot down, according to Cory Kasimov, the JPMorgan analyst who follows the company.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs